英为财情Investing.com - 强生公司 (NYSE: JNJ)星期二发布了第一季度的财报，数据显示，公司营收高于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$2.77，总营收为$21.89B，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$21.57B，每股收益为$2.58. 今年以来，强生公司的股价累计上涨了 ...

QNET, a global wellness and lifestyle-focused direct selling company committed to offering innovative and high-quality ...

《中时新闻网》前身为《中时电子报》，于1995年创立，是全台第一家且歷史最悠久的网路媒体，开启新闻数位时代。近来以最具影响力的政治新闻引领先驱外，首创娱乐、生活、社会专题式新闻报导，带起同业间仿效风潮；精辟的言论、财经、国际、两岸、军事、体育、网推频 ...

Other analysts have also issued reports about the stock. Maxim Group began coverage on shares of Anixa Biosciences in a report on Friday, March 21st. They issued a “buy” rating and a $10.00 ...

Get Our Latest Analysis on Knight Therapeutics Knight Therapeutics Price Performance Shares of TSE GUD opened at C$6.00 on Wednesday. The company has a quick ratio of 1.79, a current ratio of 3.36 ...

Belite Bio reported 4Q net loss of $36.1M and gross proceeds of $15M. The Phase III DRAGON trial is expected to be completed by 4Q25 and data released by early 2026. Feel unsure about the market ...

周二，市值21.6亿美元的生物科技公司Belite Bio, Inc. (NASDAQ:BLTE)在发布2024年财务报告后，获得H.C. Wainwright维持"买入"评级，目标价保持在100.00美元。根据InvestingPro数据显示，分析师给出的目标价区间在50美元至110美元之间，反映出市场预期的多样性。该公司分析师Yi ...

Senior Managing Partner of Belite Capital Gerson Gibbs joined Good Day DC for a look at what you can expect from the stock market this week. BREAKING: Supreme Court unanimously rules against Trump ...

Tom Lin, Chairman and CEO of Belite. “We are very excited with the DSMB’s recommendation and the safety profile of Tinlarebant, and we remain on track to complete the trial by the fourth quarter of ...